JERUSALEM, Israel, June 3, 2026 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for severe multidrug-resistant infections, announced today that the first patients in a Phase II trial (NCT06087536)1 have been dosed with its lead compound OMN6, a first-in-class antimicrobial targeting severe multidrug-resistant Acinetobacter baumannii infections associated with high mortality and limited treatment options. The patients were treated at Rabin Medical Center (Beilinson Hospital), Samson Assuta Ashdod University Hospital, and Shamir Medical Center in Israel.

Read more here.